June 15, 2022 – Winnipeg, Manitoba
Research Manitoba, in collaboration with Novartis Canada and MindSet, is proud to announce an exciting new research project which will focus on the evaluation of LDL cholesterol treatment, cardiovascular events, and healthcare costs among individuals with atherosclerotic cardiovascular disease (ASCVD) and Familial Hypercholesterolemia (FH) in Manitoba.
Currently, ASCVD is a leading cause of morbidity and mortality worldwide and FH is estimated at about 1/300 persons worldwide. ASCVD is a hardening and narrowing of the arteries caused by cholesterol plaques lining the artery over time and can put blood flow at risk as arteries become blocked. FH is a hereditary disorder and causes LDL (bad) cholesterol levels to be very high. The condition begins at birth and can cause heart attacks at an early age. Canadian Journal of Cardiology, Volume 34 (2018) 1553-1563
Research Manitoba and Novartis Canada are providing the financial investment over two years and MindSet (Manitoba’s INtegrated Data Set) and Novartis are collaborating to operationalize the research project. The project objective is to identify the most effective strategy for lowering LDL-C and costs.
“The health of Manitobans and strengthening healthcare in Manitoba is our government’s top priority,” said Health Minister Audrey Gordon. “Our government continues to search for and support innovative ways to address significant challenges to the health-care system exemplified by this research collaboration with Novartis Canada, MindSet and Research Manitoba. We look forward to the affect research such as this will have on the health-care system in Manitoba and for all Canadians.”
“We are pleased to collaborate with Novartis Canada and MindSet on this innovative research project that will use integrated real-world data to evaluate the impact of a therapeutic treatment to improve patient health outcomes,” said Karen Dunlop, CEO of Research Manitoba.